Results of the double-blinded and initial open-label phases of the ELECT Study demonstrate the effectiveness of lanreotide in controlling diarrhea and flushing in patients with NETs presenting with carcinoid syndrome.
Development of carcinoid syndrome has a profound effect on cost of care for patients with neuroendocrine tumors (NETs).
Patients who receieved lanreotide depot had a significantly lower percentage of days when rescue octreotide was used compared with placebo.
Lanreotide decreased the proportion of days patients had flushing and diarrhea compared with placebo, even in patients previously responsive to rescue therapy with octreotide.
Sign Up for Free e-newsletters
- Study Finds Association Between Folate Intake and Risk of Cutaneous Melanoma
- Melanoma Outcomes Improved With Nivolumab Alone or Plus Ipilimumab
- Encorafenib, Binimetinib Combination Receives FDA Approval for Mutation-Positive Melanoma
- Certain Risk Factors May Decrease Overall Survival in Pediatric B-NHL
- Oral Contraceptive Use May Not Be Associated With Increased Melanoma Risk
- Implementing an Ambulatory Adherence Program May Improve Oral Anticancer Medications Compliance
- Exercise Habits Influence Mortality in Adult Survivors of Childhood Cancer
- Managing Dyspnea With Fentanyl in Patients With Cancer at End of Life
- CALM: A Depression Intervention for Cancer Patients at the End of Life
- High BMI Among Premenopausal Women May Improve Risk for Breast Cancer
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|